If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysgeusia been reported in patients taking Zepbound® (tirzepatide)?
In 2 pooled clinical trials, 0.4% of patients treated with tirzepatide reported experiencing dysgeusia, while no patients in the placebo group reported dysgeusia.
See important safety information, including boxed warning, in the attached prescribing information.
Dysgeusia
Dysgeusia is a condition that changes a person’s sense of taste, making everything taste sweet, sour, bitter, or metallic.1
In a pool of SURMOUNT-1 and SURMOUNT-2 studies, dysgeusia was reported by 0.4% of tirzepatide-treated patients and no placebo-treated patients.2
Enclosed Prescribing Information
References
1Dysgeusia. Boston Medical Center. Updated April 2020. Accessed November 13, 2024. https://www.bmc.org/patient-care/conditions-we-treat/db/dysgeusia
2Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: November 11, 2024